Rani Therapeutics Holdings, Inc. cash flow to debt ratio of -433.40% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Rani Therapeutics Holdings, Inc.'s free cash flow has increased -47.43% from $-35.76M last year to $-18.80M, signaling increasing performance

Rani Therapeutics Holdings, Inc.'s debt to equity ratio is 0.14, which means that the company's assets are healthy financed, signaling financial stability.

Rani Therapeutics Holdings, Inc.'s debt has decreased relative to shareholder equity from 14.91 last year to 0.14 today, signaling strengthened financials

Rani Therapeutics Holdings, Inc. has a net cash position, so leverage is healthy.

Rani Therapeutics Holdings, Inc.'s interest coverage ratio is -17.00, which means that the company struggles to meet interest obligations, signaling financial risk.

Rani Therapeutics Holdings, Inc.'s profit margin has increased (-68.18%) in the last year from -2.92K% to -929.06%, signaling increasing performance

Rani Therapeutics Holdings, Inc.'s short-term assets of $53.32M exceed its short-term liabilities of $12.67M

Rani Therapeutics Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Rani Therapeutics Holdings, Inc.'s return on equity of -245.45%, is lower than 15.00%, indicating bad performance

Rani Therapeutics Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rani Therapeutics Holdings, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Rani Therapeutics Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Rani Therapeutics Holdings, Inc. has negative free cash flow, indicating cash burn

Rani Therapeutics Holdings, Inc.'s yearly earnings has increased -1.15% since last year from $-30.02M to $-29.67M, signaling increasing performance

Rani Therapeutics Holdings, Inc.'s yearly revenue has decreased 100.00% since last year from $1.03M to $0.00, signaling decreasing performance

ROIC -87.72% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Rani Therapeutics Holdings, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Rani Therapeutics Holdings, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Rani Therapeutics Holdings, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Rani Therapeutics Holdings, Inc. has insufficient data to evaluate this check.

Rani Therapeutics Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rani Therapeutics Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Rani Therapeutics Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Rani Therapeutics Holdings, Inc. has insufficient data to evaluate this check.

Rani Therapeutics Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rani Therapeutics Holdings, Inc. has a price-to-book ratio of 3.93x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Rani Therapeutics Holdings, Inc. has a price-to-sales ratio of 44.14x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue